Predicting pregnancy complications with high-plex proteomics
A SomaLogic boutique webinar
Predicting pregnancy complications with high-plex proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth. In this webinar, Dr. Lucy Bartho delves into the transformative role of SomaLogic’s SomaScan® assay in their biomarker discovery endeavors. She will also elaborate on how this technology has facilitated the development of clinical tools for the early identification of preeclampsia and fetal growth restriction.
Lucy Bartho, PhD
Dr. Lucy Bartho is a postdoctoral fellow from the Translational Obstetrics Group at the University of Melbourne, co-led by Professor Stephen Tong and Professor Tu’uhevaha Kaitu’u-Lino. The team of 10-15 scientists and clinician-scientists is dedicated to developing diagnostics and therapeutics aimed at enhancing the care of pregnant women and their fetuses. The research arising from the team focuses on identifying novel biomarkers for predicting pregnancy complications, developing treatments for ectopic pregnancy and preeclampsia, and elucidating the pathogenesis of these conditions.
Predicting pregnancy complications with high-plex proteomics
A presentation by Lucy Bartho, PhD
More webinars
WebinarIdentifying Biomarkers for IBD Diagnosis and Management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
WebinarYoung blood for old brains and the quest to slow brain aging
Aging leads to the degradation of function in nearly all tissues and organs. This process is marked by significant shifts in gene expression and changes in concentrations of all types of biological molecules. Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism
WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.